Cite

HARVARD Citation

    Asselah, T. et al. (2020). Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study. Liver international. pp. 1042-1051. [Online]. 
  
Back to record